TY - JOUR
T1 - Establishment and characterization of the NCC–SS1–C1 synovial sarcoma cell line
AU - Kito, Fusako
AU - Oyama, Rieko
AU - Takai, Yoko
AU - Sakumoto, Marimu
AU - Shiozawa, Kumiko
AU - Qiao, Zhiwei
AU - Uehara, Takenori
AU - Yoshida, Akihiko
AU - Kawai, Akira
AU - Kondo, Tadashi
N1 - Funding Information:
Funding This work was supported by the National Cancer Center Research and Development Fund [26-A-3, 26-A-9, and 29-A-2].
Publisher Copyright:
© 2018, Japan Human Cell Society and Springer Japan KK, part of Springer Nature.
PY - 2018/4/1
Y1 - 2018/4/1
N2 - Synovial sarcoma is an aggressive mesenchymal malignancy characterized by unique gene fusions. Tissue culture cells are essential tools for further understanding tumorigenesis and anti-cancer drug development; however, only a limited number of well-characterized synovial sarcoma cell lines exist. Thus, the objective of this study was to establish a patient-derived synovial sarcoma cell line. We established a synovial sarcoma cell line from tumor tissue isolated from a 72-year-old female patient. Prepared cells were analyzed for the presence of gene fusions by fluorescence in situ hybridization, RT-PCR, and karyotyping. In addition, the resulting cell line was characterized by viability, short tandem repeat, colony and spheroid formation, and invasion analyses. Differences in gene enrichment between the primary tumor and cell line were examined by mass spectrometric protein expression profiling and KEGG pathway analysis. Our analyses revealed that the primary tumor and NCC–SS1–C1 cell line harbored the SS18–SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles. In vitro analyses also confirmed that the established cell line harbored invasive, colony-forming, and spheroid-forming potentials. Moreover, drug screening with chemotherapeutic agents and tyrosine kinase inhibitors revealed that doxorubicin, a subset of tyrosine kinase inhibitors, and several molecular targeting drugs markedly decreased NCC–SS1–C1 cell viability. Results from the present study support that the NCC–SS1–C1 cell line will be an effective tool for sarcoma research.
AB - Synovial sarcoma is an aggressive mesenchymal malignancy characterized by unique gene fusions. Tissue culture cells are essential tools for further understanding tumorigenesis and anti-cancer drug development; however, only a limited number of well-characterized synovial sarcoma cell lines exist. Thus, the objective of this study was to establish a patient-derived synovial sarcoma cell line. We established a synovial sarcoma cell line from tumor tissue isolated from a 72-year-old female patient. Prepared cells were analyzed for the presence of gene fusions by fluorescence in situ hybridization, RT-PCR, and karyotyping. In addition, the resulting cell line was characterized by viability, short tandem repeat, colony and spheroid formation, and invasion analyses. Differences in gene enrichment between the primary tumor and cell line were examined by mass spectrometric protein expression profiling and KEGG pathway analysis. Our analyses revealed that the primary tumor and NCC–SS1–C1 cell line harbored the SS18–SSX1 fusion gene typical of synovial sarcoma and similar proteomics profiles. In vitro analyses also confirmed that the established cell line harbored invasive, colony-forming, and spheroid-forming potentials. Moreover, drug screening with chemotherapeutic agents and tyrosine kinase inhibitors revealed that doxorubicin, a subset of tyrosine kinase inhibitors, and several molecular targeting drugs markedly decreased NCC–SS1–C1 cell viability. Results from the present study support that the NCC–SS1–C1 cell line will be an effective tool for sarcoma research.
KW - Drug response
KW - Primary culture cells
KW - Proteome
KW - Synovial sarcoma
UR - http://www.scopus.com/inward/record.url?scp=85042114633&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042114633&partnerID=8YFLogxK
U2 - 10.1007/s13577-018-0199-9
DO - 10.1007/s13577-018-0199-9
M3 - Article
C2 - 29450702
AN - SCOPUS:85042114633
SN - 0914-7470
VL - 31
SP - 167
EP - 174
JO - Human Cell
JF - Human Cell
IS - 2
ER -